Single Center Experience with a 4-Week (177)Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: The optimal treatment regimen with (177)Lu-PSMA-617 for metastatic castration-resistant prostate cancer patients is not known. In this retrospective analysis, the efficacy and impact of a four-week treatment interval on patient outcome and safety were investigated. A significant PSA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemppainen, Jukka, Kangasmäki, Aki, Malaspina, Simona, Pape, Bernd, Jalomäki, Jarno, Kairemo, Kalevi, Kononen, Juha, Joensuu, Timo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776672/
https://www.ncbi.nlm.nih.gov/pubmed/36551641
http://dx.doi.org/10.3390/cancers14246155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776672/
https://www.ncbi.nlm.nih.gov/pubmed/36551641
http://dx.doi.org/10.3390/cancers14246155

Ejemplares similares